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Abstract
Background: In areas of stable transmission, malaria during pregnancy is associated with severe
maternal and foetal outcomes, especially low birth weight (LBW). To prevent these complications,
weekly chloroquine (CQ) chemoprophylaxis is now being replaced by intermittent preventive
treatment with sulfadoxine-pyrimethamine in West Africa. The prevalence of placental malaria and
its burden on LBW were assessed in Benin to evaluate the efficacy of weekly CQ
chemoprophylaxis, prior to its replacement by intermittent preventive treatment.
Methods: In two maternity clinics in Ouidah, an observational study was conducted between April
2004 and April 2005. At each delivery, placental blood smears were examined for malaria infection
and women were interviewed on their pregnancy history including CQ intake and dosage. CQ was
measured in the urine of a sub-sample (n = 166). Multiple logistic and linear regression were used
to assess factors associated with LBW and placental malaria.
Results: Among 1090 singleton live births, prevalence of placental malaria and LBW were 16% and
17% respectively. After adjustment, there was a non-significant association between placental
malaria and LBW (adjusted OR = 1.43; P = 0.10). Multiple linear regression showed a positive
association between placental malaria and decreased birth weight in primigravidae. More than 98%
of the women reported regular chemoprophylaxis and CQ was detectable in 99% of urine samples.
Protection from LBW was high in women reporting regular CQ prophylaxis, with a strong
duration-effect relationship (test for linear trend: P < 0,001).
Conclusion:  Despite high parasite resistance and limited effect on placental malaria, a CQ
chemoprophylaxis taken at adequate doses showed to be still effective in reducing LBW in Benin.
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Background
In malaria endemic countries, pregnant women are at
increased risk of Plasmodium falciparum infection [1,2]
which leads to increased morbidity and mortality for the
mother and her child. In areas of stable transmission,
where women have developed acquired malaria immu-
nity, malaria during pregnancy often does not cause
symptomatic infection, although it increases the risk for
maternal anaemia or death, and low birth weight (LBW)
[3,4]. LBW is an important risk factor for infant mortality
[5]. It was estimated that around 100,000 infant deaths
occur annually in malaria endemic areas in Africa due to
pregnancy associated malaria [6]. In these areas, primi-
gravidae have higher prevalence of placental malaria and
its associated complications [7,8]. This relates to the prop-
erty of parasitized erythrocytes to adhere to chondroitin
sulphate A (CSA) by means of parasite variant surface
antigens (VSA) expressed on the surface of infected eryth-
rocytes. These induce cytoadherence inhibiting VSACSA-
specific antibodies which increase in prevalence with
increasing parity [9,10].
To prevent the adverse effects of malaria during preg-
nancy, the World Health Organization (WHO) and most
African governments including Benin recommended a
weekly chloroquine (CQ) chemoprophylaxis during preg-
nancy (300 mg per week) until the mid 1990s. Because of
the poor compliance of women and the increasing rates of
P. falciparum resistance to CQ [11], the WHO changed its
recommendation to intermittent preventive treatment
(IPT), which involves the administration of treatment
doses of an antimalarial drug combination (sulfadoxine-
pyrimethamine [SP]), given during monthly antenatal
care (ANC) visits twice in pregnancy during the second
and third trimesters. The efficacy of SP IPT has been stud-
ied mostly in East Africa, and has shown reduced preva-
lence of severe maternal anaemia and LBW [12,13].
However, resistance to SP has been increasing, especially
in West Africa and there is a need to evaluate the sue of
alternative antimalarial drugs [14].
The Beninese government has recommended SP IPT for
pregnant women since the end of 2004, but this strategy
is only now commencing. Weekly CQ prophylaxis in
pregnancy has been official policy for the past 20 years in
most of the country, although this intervention had not
been evaluated previously in Benin. The aim of this study
was to assess current prevalence of placental malaria and
LBW in an observational study in Ouidah, in order to esti-
mate the efficacy of weekly CQ chemoprophylaxis in preg-
nant women.
Methods
Study site and population
The study was conducted from 15th April 2004 to 14th
April 2005 in the city of Ouidah, a semi-rural town of
approximately 38,000 inhabitants in southern Benin,
located 30 km west of Cotonou. In this area, malaria
transmission is high year round peaking during the rainy
seasons, from April to June, and September to October. In
vivo CQ resistance in children, defined as clinical treat-
ment failure by day 14, was estimated in 2002 to range
between 15% to 61.3%, and SP resistance between 3.3%
to 45.9%, dependent on area (Beninese National Malaria
Control Program, unpublished data). In Ouidah there is a
prevalence of 87.5% resistance to CQ and 50% to SP
(Aubouy, unpublished data). HIV prevalence in the gen-
eral population is approximately 2% [15]. Insecticide
treated nets (ITN) are widely used, especially among preg-
nant women who can obtain them at the time of their
ANC visits.
The study was performed in the two main city maternity
clinics, Kindji and Hopital de Zone (the latter being also a
tertiary referral centre). All pregnant women who deliv-
ered in either clinic during the study period were prospec-
tively enrolled after providing oral consent. They were
excluded if gestation was less than 22 weeks, in order to
exclude early abortions. Ethical clearance was obtained
from the Beninese Ministry of Health.
Study design and variables
Midwives collected data using a standardized question-
naire. The following variables were collected : socio-
demographic factors (age, place of living, school attend-
ance, marital status), obstetrical past history (gravidity,
parity), pregnancy related factors (number of ANC visits,
reported anaemia, oedema, high blood pressure -> 140-90
mm Hg-, acute malaria symptoms during the course of
pregnancy), malaria prevention measures (chemoprophy-
laxis and use of bed nets), and infant characteristics (vital
status at birth, birth weight, sex, twins, malformation).
Information was obtained from women at delivery and
validated with data available in ANC records, such as the
estimated gestational age, the number and date of ANC
visits, complications of pregnancy, and the date of CQ
prescription either for prophylaxis or treatment.
LBW was defined as birth weight < 2500 g, prematurity as
gestational age < 37 weeks. High ANC attendance was
defined as more than three ANC visits during the course
of pregnancy.
Midwives prepared thick and thin malaria smears from
intervillous blood. Compliance with CQ chemoprophy-
laxis was assessed using a sample of 166 women whose
urine was obtained at delivery for analysis for CQ metab-Malaria Journal 2007, 6:27 http://www.malariajournal.com/content/6/1/27
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olites. This sample included women delivered between
October 2004 and March 2005, seen on the occasion of
antenatal visits, who accepted to provide a urine sample
to the midwives, regardless to their declared chemoproph-
ylaxis.
Biological methods
Placental blood smears were obtained from the maternal
side of the placenta and stained with Giemsa, and read at
the Zone Hospital laboratory by experienced parasitology
technicians. Samples were recorded as positive for placen-
tal malaria if an asexual-stage P. falciparum parasite was
detected, after examination of 200 microscope fields.
Malaria pigment was also searched in erythrocytes and/or
circulating monocytes, as an indirect indicator for active
infection. Placental histology was not performed.
A Haskins semi-quantitative colorimetric method, modi-
fied by Mount, was used to quantify CQ in urine [16]. The
samples colour intensity was read against an optical col-
our scale (corresponding to the concentrations: 0; 1; 1.5;
3; 6 and 18 µg/ml). A urine CQ concentration of ≥3 µg/
ml, measured by this method, has been shown to be con-
sistent with the ingestion of 300 mg CQ within the previ-
ous seven days [17]. This threshold was used to indicate
good compliance with CQ chemoprophylaxis.
Statistical analysis
Data were analysed using the SAS software, 8.1 (SAS Insti-
tute, Cary, NC). Only live singleton births were studied.
After a global description (number and percentage for cat-
egorical data, mean and range for quantitative data), mul-
tivariate logistic regression and multiple linear regression
analyses were performed to study respectively the associa-
tion of LBW (categorical) and birth weight (quantitative)
with placental malaria adjusting for covariates, using a
backward stepwise approach. These analyses were per-
formed to answer different questions: logistic regression
provided an operational measure of the factors associated
with LBW which was the main outcome; multiple linear
regression was more powerful to detect weaker associa-
tions with birth weight. Two other variables were included
in the models: maternity clinic and gravidity. Other varia-
bles included were those with P < 0.20 in the univariate
analysis.
To assess the efficacy of interventions (CQ chemoprophy-
laxis and use of bed nets), we performed logistic regres-
sion analyses on LBW and placental malaria, adjusted for
gravidity and ANC attendance.
In the final models, all interactions between gravidity and
other covariates were tested. For significant interactions,
results were stratified (primigravidae versus multigravi-
dae); otherwise they were simply adjusted for gravidity.
Results
Study population
A total of 1,176 women were enrolled at delivery, 712 in
Kindji (60%) and 464 in the Zone Hospital (40%).
To check the exhaustiveness of these data collected by
midwives, they were compared to those available in the
maternity clinics birth records, and very few deliveries
seem to have been missed (less than 50 during the whole
study year). Such missing data were related to high risk
deliveries (e.g. a woman referred in the maternity for
urgent caesarean section, thus not managed by midwives,
unable to complete the questionnaire or to collect the pla-
centa).
There were 55 stillbirths (seven from twin births), and 38
sets of twins, thus 1090 live singleton births were ana-
lysed. Mother and infant characteristics are detailed in
Table 1. The study participants were on average 25.5 years
old (range: 13–44), and 25% (n = 267) were primigravi-
dae (mean gravidity = 3, range: 1–12). The median
number of ANC visits in the course of pregnancy was four
(range: 0–12), and only six women did not attend antena-
tal facilities. ANC visits were usually monthly, and their
number was directly related to the period between the first
ANC visit and delivery. Symptoms of acute malaria (fever)
during pregnancy were reported in 300 women (28%),
although less than 10% of these (29/300) had a blood
film and only five of these had P. falciparum present (2%).
Treatment was usually with CQ, administered orally
(72%). Mean gestational age at delivery was 39 weeks
(range: 26–43), and 114 infants (11%) were estimated to
be premature (< 37 weeks).
LBW and placental malaria
Mean birth weight was 2,850 g (range: 800–5,000), and
171 infants (16%) had a LBW (24% in primigravidae and
13% in multigravidae, P < 0,001). The prevalence of pla-
cental malaria was 17% (176 of the1052 placental blood
samples collected); 27% in primigravidae and 13% in
multigravidae (P < 0.001). Monthly variation of LBW and
placental malaria prevalence are shown in figure 1. Pla-
cental malaria had higher prevalence between July and
September 2004 (with main peak of 28.6% in August)
and in February 2005 (chi-square goodness-of-fit test
comparing the observed monthly distribution to a uni-
form distribution : P = 0.052). LBW prevalence showed
smaller monthly variations (P = 0.82).
Results of the univariate and multivariate logistic regres-
sion analyses of factors associated with LBW are presented
in Table 2. In univariate analysis, placental malaria was
associated with LBW (odds ratio [OR] = 1.76; 95% confi-
dence interval [CI] = 1.18; 2.62). Other unadjusted risk
factors for LBW were primigravidae (OR = 2.05; 95% CI =Malaria Journal 2007, 6:27 http://www.malariajournal.com/content/6/1/27
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1.45; 2.90), young maternal age, anaemia, low number of
ANC visits and female infant. After adjustment in the mul-
tivariate model, placental malaria was not significantly
associated with LBW (P = 0.10). An increased LBW risk
was observed in primigravidae and with high maternal
blood pressure, a low number of ANC visits, or a female
infant. Young maternal age was strongly associated with
LBW in univariate analysis, but not in the multivariate
model after adjustment for gravidae.
Multiple linear regression showed a clinic effect as birth
weight was 72 g [9; 135] higher in the Zone hospital. In
this model, gravidity modified the effect of placental
malaria infection on birth weight (interaction test: P =
0.02): in primigravidae, placental malaria infection was
associated with decreased mean birth weight (regression
coefficient = -180 g [-342; -18], P = 0.01), although no
association was shown in multigravidae (P = 0.79).
Antimalarial prevention measures
Self-reported compliance with antimalarial prophylaxis is
summarized in Table 3. Seventy-five percent of women (n
= 764) reported use of bed nets. All but six reported use of
CQ chemoprophylaxis. More than 95% (n = 1,006)
declared they had taken an adequate CQ dosage (three
100 mg tablets per week), for a mean duration of five
months, commencing at four months gestation.
Of the 166 women whose urine samples were tested for
CQ, seven (4.2%) reported fever during the last month of
pregnancy, and four (2.4%) had received a curative dose
of CQ. These four women were excluded from further
analyses. Of the remaining 162 women, only two had no
CQ detectable in urine. Low concentrations (< 3 µg/ml)
were present in 28% and high concentrations (consistent
with the ingestion of 300 mg of CQ within seven days) in
72%.
Table 4 shows the effects of antimalarial prevention meas-
ures (prophylaxis and bed nets) on prevalence of placen-
tal malaria and LBW. For placental infection, prevention
measures (bed nets or CQ) were not found to be protec-
tive. These results remained unchanged when considering
the presence of malaria pigment in erythrocytes. There
was a highly significant association between the duration
of chemoprophylaxis and the occurrence of LBW
(adjusted OR = 4.61; 95% CI = 2.27; 9.36 for the compar-
ison between the lowest and highest duration quartiles),
and a significant duration-effect relationship (chi-square
for linear trend: P < 0.001).
Prophylaxis reported to be taken during the last trimester
showed a protective effect on LBW (P < 0,001).
Discussion
In a one-year observation of deliveries in Ouidah, where
women were systematically prescribed weekly CQ chemo-
prophylaxis, CQ was still effective in reducing LBW
despite its limited effect on placental malaria.
Placental malaria has been often described as a major
cause of LBW [18], but most studies did not adjust for
other risk factors. In the present study, we performed mul-
tivariate analyses and showed a borderline effect of pla-
cental malaria on LBW (P = 0.10). However, in
Table 1: Mother and infant characteristics, singleton live births, 
Kindji and Hopital de Zone maternity clinics, 2004–2005
Characteristic n % N
General characteristics
Maternity clinic 1090
Kindji 693 63.6
Hopital de Zone 397 36.4
Season at delivery 1090
Rainy season 435 39.9
Dry season 655 60.1
Mother characteristics
Age (years) (quartiles) 1072
≥20 255 23.8
21–25 373 34.8
26–30 244 22.7
> 30 200 18.7
Place of living 1090
urban 689 63.2
rural 205 18.8
unknown (not reported or not localized) 196 18.0
School attendance 1051
none 527 50.1
primary 359 34.2
secondary, superior 165 15.7
Gravidity
primigravidae 267 24.5 1090
multigravidae 823 75.5
Number of ANC visits
0–3 400 37.2 1076
> 3 676 62.8
Reported complications during pregnancy
high blood pressure 56 5.2 1069
legs oedema 91 8.5 1075
anaemia 57 5.3 1068
proteinuria 91 9.2 992
Reported symptoms of acute malaria 300 28.0 1071
Placental malaria 176 16.7 1052
Infant characteristics
LBW (< 2500 g) 171 15.7 1087
Sex
female 522 47.9 1090
male 568 52.1
Malformation* 14 1.5 909
ANC: antenatal care; LBW: low birth weight
N: total number of women
(*) Most reported malformations: surplus finger (n = 4), hypotrophy 
(n = 2), palate malformation (n = 1), hydrocephaly (n = 1), other 
polymalformative syndromesMalaria Journal 2007, 6:27 http://www.malariajournal.com/content/6/1/27
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primigravidae, mean birth weight was significantly lower
with malaria infection (P = 0.01, multilinear regression),
thus confirming that this sub-group is at higher risk for
the adverse consequences of gestational malaria.
Female infant sex and high maternal blood pressure are
associated risk factors for LBW [19], as well as poor ANC
attendance [20]. The latter may reflect different interven-
tions, including standard obstetrical care, malaria preven-
tion and nutritional advice, or a combination of these
factors.
In spite of fluctuations in the transmission of malaria,
there was no clear effect of the rainy season on the occur-
rence of LBW, probably because malaria acts as one of the
multiple determinants of LBW (like nutritional status
[21,22] that may also interfere with foetal growth).
Maternal HIV status and nutritional factors, which may
have an influence on LBW [19,21,23], were not available,
although where HIV prevalence does not exceed 2% its
influence in LBW will be small [14].
In this Beninese population, there was a high ANC attend-
ance and frequent use of bed nets. Compliance with anti-
malarial prophylaxis was high as 98% of women declared
to have taken CQ chemoprophylaxis, during the five
months preceding delivery, and most with adequate dos-
age. This was consistent with the CQ assay in urine in
which 99% had detectable CQ. In other African settings,
self-reported compliance with prophylaxis has been asso-
ciated with low levels (< 20%) of amino-quinolines in
urine [24]. This was not the case in Benin, where all indi-
cators showed good compliance. The WHO [25] had
already pointed Benin as one of the African countries
where ANC attendance was the highest and the earliest in
the course of pregnancy, with one of the highest coverages
for chemoprophylaxis and use of bed nets among preg-
nant women.
An interesting and unexpected result was that despite low
CQ anti-parasite efficacy (nearly 90% in vivo resistance
measured in children in Ouidah in 2005, Aubouy, unpub-
lished data), CQ chemoprophylaxis showed protective
efficacy for LBW, with a significant duration-effect rela-
tionship as the longer the women took chemoprophy-
laxis, the lower the risk of LBW. This effect was most likely
to be associated with chemoprophylaxis, and not with the
number of ANC visits, since the analysis was adjusted for
this factor. Similarly, there was no differential effect of
Monthly variation of low birth weight and placental malaria prevalence in singleton live births Figure 1
Monthly variation of low birth weight and placental malaria prevalence in singleton live births. Ouidah, Kindji and 
Hopital de Zone maternity clinics, April 2004-April 2005, N = 1090.
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chemoprophylaxis on placental malaria or LBW when
comparing primigravidae and multigravidae.
Parasite resistance to chloroquine is considered to relate
to reduced efficacy in terms of birth weight and maternal
anaemia. It is one of the main reasons why CQ has been
replaced by intermittent SP in malaria prevention policies
in pregnancy [26]. However, in the 1990's, when resist-
ance to CQ was developing in Western Africa, it was
shown that with moderate resistance there was still good
protection of the foetus from the main consequences of
placental malaria [27]. The mechanism by which placen-
tal malaria leads to LBW is not clearly understood. This
association was shown to be parasite density-dependent,
with higher risks for LBW in women with high para-
sitemias [21], indicating that parasite accumulation in the
placenta was contributory. Activity of CQ on residual sen-
sitive P. falciparum strains could lead to a partial reduction
in placental parasitemia, and decrease of LBW.
In addition to parasite resistance, another reason for
abandoning CQ prophylaxis in pregnant women in sub-
Saharan Africa is the reported poor compliance in preg-
nancy [28]. This is not true for Beninese women, at least
in our study area, who showed a good adherence to
prophylaxis and also at adequate dosage. The combined
effect of these two factors (partial antimalarial activity of
CQ and good compliance) is probably the explanation for
the discrepancy between presumed P. falciparum resist-
ance to CQ and a protective effect for reducing risk of
LBW.
Conclusion
From a public health point of view, these results and pre-
vious studies [27] indicate that there may be an important
time interval between the onset of P. falciparum resistance
to CQ and the subsequent development of adverse conse-
quences to the foetus health. Although a return to CQ
prophylaxis in Africa cannot be seriously considered,
Table 2: Factors associated with LBW by logistic regression
Characteristic* Univariate analysis Multivariate analysis N = 995
Crude OR (95% CI) P** Adjusted OR (95% CI) P**
Placental malaria 0.006 0.10
no 1.00 1.00
yes 1.76 (1.18–2.62) 1.43 (0.93–2.20)
Maternity clinic 0.46***
Kindji 1.00 - -
Hopital de Zone 0.88 (0.62–1.24)
Number of ANC visits 0.009 0.03
> 3 1.00 1.00
≥3 1.56 (1.12–2.17) 1.49 (1.05–2.13)
Primigravidity <0.001 <0.001
no 1.00 1.00
yes 2.05 (1.45–2.90) 2.05 (1.41–2.97)
Maternal age 0.006***
≥20 1.00
[20–25] 0.60 (0.40–0.91) - -
[25–30] 0.52 (0.33–0.84)
> 30 0.45 (0.27–0.76)
Maternal high blood
pressure 0.11 0.02
no 1.00 1.00
yes 1.70 (0.89–3.23) 2.17 (1.10–4.22)
Maternal anaemia 0.02***
no 1.00 - -
yes 2.05 (1.11–3.79)
Infant Sex <0.001 0.001
male 1.00 1.00
female 1.75 (1.26–2.44) 1.79 (1.26–2.56)
LBW: low birth weight; ANC: antenatal care; OR: odds ratio; CI: confidence interval
(*) Only variables with P value < 0.20 in univariate analysis are shown
(**) P values calculated with the Wald test
(***) Maternity clinic was not included in the model (P > 0.20); anaemia and maternal age did not remain significant in the multivariate model after 
adjustmentMalaria Journal 2007, 6:27 http://www.malariajournal.com/content/6/1/27
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Table 4: Effects of the use of bed nets and CQ on placental malaria and LBW
Placental malaria LBW
% AOR* (95% CI) P** % AOR* (95% CI) P**
Use of bed nets 0.16 0.45
no 21.7 1.00 19.1 1.00
yes 15.4 0.76 (0.51–1.11) 14.2 0.86 (0.58–1.27)
Reported duration of CQ chemoprophylaxis (months) 0.33 <0.001***
< 4 18.0 1.57 (0.82–3.00) 23.1 3.96 (1.9–8.28)
[4–5] 19.2 1.69 (0.97–2.97) 18.0 2.93 (1.50–5.75)
[5–7] 15.7 1.37 (0.77–2.44) 9.8 1.52 (0.74–3.13)
≥7 11.7 1.00 6.5 1.00
Reported CQ intake during 1st trimester 0.43 0.35
no 16.4 1.00 16.6 1.00
yes 16.9 1.16 (0.80–1.70) 14.6 1.20 (0.82–1.76)
Reported CQ intake during 2nd trimester 0.72 0.37
no 19.0 1.00 15.7 1.00
yes 16.5 0.89 (0.48–1.68) 15.1 1.35 (0.70–2.59)
Reported CQ intake during 3rd trimester 0.67 <0.001
no 21.7 1.00 46.2 1.00
yes 16.5 0.80 (0.28–2.26) 14.2 0.24 (0.11–0.56)
LBW: low birth weight; ANC: antenatal care; AOR: adjusted odds ratio; CI: confidence interval; CQ: chloroquine
(*) Odds ratios adjusted for primigravidity and number of ANC visits
(**) P values calculated with the Wald test
(***) Univariate Chi-square test for linear trend: P < 0,001
Table 3: Self-reported compliance to antimalarial prophylaxis
Characteristic n%
Chemoprophylaxis (N = 1081)
CQ 1065 98.5
other 10 0.9
none 60 . 6
CQ dosage (tablets per week) (N = 1057)*
3 1006 95.1
< 3 25 2.4
> 3 26 2.5
Duration of CQ chemoprophylaxis (months) (N = 1040)* (quartiles)
< 4 246 23.2
[4–5] 348 33.7
[5–7] 257 24.9
≥7 189 18.3
CQ intake during 1st trimester** (N = 1056)* 527 49.9
CQ intake during 2nd trimester** (N = 1044)* 961 92.0
CQ intake during 3rd trimester** (N = 1051)* 1025 97.5
Use of bed nets (N = 1010) 764 75.6
ANC: antenatal care; CQ: chloroquine
(*) The 10 women taking another drug than CQ were not considered here
(**) CQ was considered to be taken during the 1st, 2nd or 3rd trimester if the woman said she had taken CQ at least once in the corresponding 
period.Malaria Journal 2007, 6:27 http://www.malariajournal.com/content/6/1/27
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these findings could be relevant to SP IPT prevention pol-
icy. As resistance to SP is rapidly spreading in endemic
areas, it is essential to find alternative drugs for IPT. How-
ever, residual activity of SP may also be sufficient to main-
tain benefits to the foetus while alternative antimalarials
are evaluated.
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